Cancer Clinical Trials

Find a clinical trial, talk with your doctor to learn if you are eligible.


*List last updated, May 2021.

Cancer Type Trial Name Site
Breast
OTS1070103:A Phase I Study of OTS167PO,a MELK inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients with Advanced Breast 
Cancer and Dose-Expansion Study in Patients with Triple Negative Breast cancer
 Norwalk
NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer  Norwalk/Danbury
SGNLVA-001:A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer  Norwalk
SGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer  Norwalk
WO41544: A PhaseIII, Randomized, Double-blind,Placebo-controlled Study evaluating The efficacy and safety of GDC-0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients with  Metastatic Breast Cancer.PIK3CA-Mutant, Hormone receptor positive, Her2-Negative Locally Advanced or or Metastatic Breast Cancer.  Norwalk
A011202:A Randomized, Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy  Norwalk / VBMC
S1418/BR006: A Randomized Phase III Trial to Evaluate Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/=1 CM Residual Invasive Cancer or Positive Lymph Nodes (>ypN+) After Neoadjuvant Chemotherapy  Norwalk/Danbury
ARV-471-mBC-101: A Phase 1/2, open label, dose escalation, and cohort expansion clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting  Norwalk
18-109: A Feasibility Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromotase Inhibitors  Norwalk
19-401: Triple Negative Breast Cancer Clinic Program at Norwalk Hospital  Norwalk
18-002: A Phase I Study of Rucaparib Administered Concurrently with Postoperative Radiotherapy in Patients with Triple Negative Breast Cancer with an Incomplete Pathologic Response Following Neoadjuvant Chemotherapy   Norwalk
19-300: Ultra-Short External Beam-Based Accelerated Partial Breast irradiation (APBI) : A phase II Toxicity Study Nested with a Non- inferiority Assessment of APBI in New Patient Cohorts  Norwalk
BO41843: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined with Palbociclib Compared with Letrozole Combined with Palbociclib in Patients with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer   Norwalk/Danbury
A011801: The COMPASSHER2 Trials ( COMprehensive  Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatnib.  Norwalk/Danbury
Breast & Lung 18-486  PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients with Oligometastatic Breast or Lung Cancer  Norwalk
Bladder A031501 PHASE III Randomized Adjuvant study of MK-3475 (pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (ambassador) versus observation
 Danbury
Lung A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
 Danbury/VBMC
E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
 Danbury/VBMC
AMG 20190009: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
 Danbury
AMG 20190294: A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (NSCLC)
 Danbury
GYN
NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
 Danbury/Norwalk
NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
 Danbury/Norwalk
NRG-GY020: “Randomized Phase III Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (DMMR) Endometrioid Endometrial Cancer.
 Danbury/Norwalk
NRG-GY006: A Randomized phase III trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, or stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal cancer.
 Danbury/Norwalk
OVAL 3018: The OVAL Study" A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
 VBMC
Pancreas 15-10: The Role of MicroRNAs in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
 Norwalk/Danbury/New Milford
16-15: Pre- and Post-Surgical Molecular Testing in Individuals with Operable Pancreatic Cancer
 Norwalk/Danbury/New Milford
16-17: A Pancreatic Cancer Screening Study in High Risk Individuals
 Norwalk/Danbury/New Milford
18-01: A Pancreatic Cancer Screening Study in High Risk Individuals Including those with Recent-Onset Diabetes Mellitus
 Norwalk/Danbury/New Milford
A021806: A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer
 Norwalk/Danbury
S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations Norwalk/Danbury 
Colon NRG-GI004/S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA  Mismatch Repair (dMMR) Metastatic Colorectal Cancer Danbury 
Prostate C3441021: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.
 Norwalk/Danbury/New Milford
Neuro A021602: Randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on prior therapy (CABINET)  Norwalk/Danbury
Translational
15-35: Serum-based Signature of Activation of the PD-1/PD-L1 Pathway in Patients with Cancer. Serial serum samples from patients starting immune-based therapies that target the PD-1/PDL-1 pathway in cancer patients.
 Norwalk/Danbury/New Milford
BB001: The Western Connecticut Health Network (WCHN), Danbury and Norwalk Hospitals Biobank - A Collection of Biospecimens and Clinical Data to Facilitate Research (GYN Biobank)
 Norwalk/Danbury/New Milford
15-101: Enumeration of circulating plasma cells in MGUS and Multiple Myeloma
 Norwalk/Danbury/New Milford
IMPACT:12-245: Genomic Profiling in Cancer Patients
 Norwalk
Advanced Cancer_Anorexia C3651010: A 6-Week, Randomized, Double-Blind, Sponsor-Open Study to assess the effect of repeated subcutaneous administration of PF-06946860 on Appetite in participants with Advanced Cancer and Anorexia, followed by an 18-week-Open-Label Treatment Period.  
Basket Trial
C2321001: A Phase I dose escalation and expanded cohort study of PF-06821497 in the treatment of adult patients with Relapsed/refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and follicular lymphoma  Norwalk
AMG 510 20190135: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
 Norwalk
ALK4230-101: Alkermes, Inc. / A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors-ARTISTRY-1Alkermes, Inc. / A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors-Alkermes, Inc. / A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors ARTISTRY-1
 Norwalk/Danbury
X

Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.

Home

Confirm